Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

TCM Formula

Phase 2Small molecule

PPeking University Cancer Hospital & Institute

1

Indications

4

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pre-FrailtyActive, not recruiting

Pre-FrailtyPhase 2

Active, not recruiting

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Pre-Frailty

NCT07597850

Clinical

Trials by Indication[1]

Adverse Effect1 trial

Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect

Completed·—·Phase 3·NCT05204758·30 enrolled

Eye Disease1 trial

Effect of Traditional Chinese Medicine on Basic Tear Secretion and Tear Cytokines in Patients With Dry Eye Disease

Unknown status·—·Phase 2·NCT04785261·60 enrolled

Fatigue1 trial

RSYR for Fatigue Reduction in Cancer Fatigue Caused by Chemotherapy

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT05229029·196 enrolled

Pre-Frailty1 trial

Effects of Traditional Chinese Medicine (TCM) Formula vs. HMB on Muscle Strength and Bone Status in Pre-Frail Elders: A Comparative Study

Active, not recruiting·TTri-Service General Hospital (TSGH)·Phase 2·NCT07597850·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for TCM Formula. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TCM Formula compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TCM Formula. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University Cancer Hospital & Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPeking University Cancer Hospital & Institute

Related News